Entrada Therapeutics, Inc. TRDA
Set alert
4.68 USD -0.43 -8.38%
As of Nov 3, 1:09 PM ET
4.62 Day range 5.08
4.37 52-week range 16.03
- YTD
- -54.46%
- 1 year
- -30.95%
- Open
- 5.08
- Prev close
- 5.11
- Mkt cap
- 182.81M
- Vol
- 153.91K
- Avg vol
- 346.66K
- EPS
- -3.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.62
- High
- 5.08
- Forward P/E
- -5.54
- Beta
- -0.27
- Short ratio
- 11.43
- Inst. own
- 80.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 18.48
- 200-d avg
- 15.77
- 1y target
- 26.43
1M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bearish | Oct 27, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 27, 2026 | 1 week ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
Analyst view
Price target (mean) 26.43 +464.5% upside
Now 4.68
- Target (low)
- 20.00
- Target (mean)
- 26.43
- Target (high)
- 29.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.664 | -0.69 – -0.62 | -0.28 | -137.1% | 12.92M | -69.1% | 5 |
| Next quarter | -0.72 | -0.86 – -0.54 | 0.68 | -205.9% | 11.95M | -79.8% | 5 |
| Current year | 1.07 | 0.91 – 1.26 | -0.20 | +637.0% | 186.51M | +44.6% | 5 |
| Next year | -3.02 | -3.74 – -2.17 | 1.07 | -381.0% | 46.74M | -74.9% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | Initiated | — | Buy |
| Nov 6, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 26, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 5, 2024 | Oppenheimer | Initiated | — | Outperform |
| Nov 27, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 22, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 24, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 8, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Aug 16, 2022 | Goldman Sachs | Maintained | — | Neutral |
| May 24, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Nov 24, 2021 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 23, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Nov 23, 2021 | Goldman Sachs | Initiated | — | Neutral |